FY2024 EPS Estimates for ADMA Biologics Raised by Analyst

ADMA Biologics, Inc. (NASDAQ:ADMA) – HC Wainwright raised their FY2024 earnings per share estimates for ADMA Biologics in a note issued to investors on Friday, November 8th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings per share of $0.55 for the year, up from their prior estimate of $0.49. HC Wainwright currently has a “Buy” rating and a $26.00 target price on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.51 per share. HC Wainwright also issued estimates for ADMA Biologics’ Q4 2024 earnings at $0.19 EPS, Q1 2025 earnings at $0.20 EPS, Q2 2025 earnings at $0.21 EPS, Q3 2025 earnings at $0.22 EPS and Q4 2025 earnings at $0.24 EPS.

A number of other equities analysts have also recently issued reports on ADMA. Raymond James boosted their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th.

ADMA Biologics Stock Down 0.6 %

Shares of NASDAQ ADMA opened at $22.48 on Monday. The firm’s fifty day moving average is $18.12 and its 200 day moving average is $13.95. ADMA Biologics has a 52 week low of $3.60 and a 52 week high of $23.64. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. The company has a market cap of $5.24 billion, a price-to-earnings ratio of 80.29 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The business had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a return on equity of 59.29% and a net margin of 17.80%. During the same period in the previous year, the firm earned $0.01 EPS.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Quest Partners LLC purchased a new position in shares of ADMA Biologics during the 2nd quarter worth $29,000. Hollencrest Capital Management bought a new stake in ADMA Biologics during the third quarter valued at about $30,000. EntryPoint Capital LLC purchased a new stake in ADMA Biologics in the first quarter worth about $31,000. CWM LLC raised its stake in shares of ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after buying an additional 4,367 shares during the period. Finally, Acadian Asset Management LLC purchased a new position in shares of ADMA Biologics during the 2nd quarter valued at about $93,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $16.90, for a total value of $408,135.00. Following the sale, the chief operating officer now owns 449,088 shares in the company, valued at approximately $7,589,587.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is currently owned by corporate insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.